Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
Kappa Agonists - an overview | ScienceDirect Topics
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect
The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist | PNAS
G protein signaling–biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists | PNAS
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
The role of the opioid system in decision making and cognitive control: A review | SpringerLink
Mu Agonist Opioids and Kappa Opioids | Download Table
A Novel Kappa Opioid Receptor Agonist May Unlock New Treatment Strategies for Pain | Pain Research Forum
A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect
Understanding opioids in veterinary medicine
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
